Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
August 2019
Investor PresentationEnerCom |The Oil & Gas Conference
Forward Looking Statements Disclaimer and DisclosuresCertain statements and information included in this presentation constitute “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on certain assumptions and analyses made by the Company’s management in light of its experience and its perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances.
These statements involve known and unknown risks and uncertainties, some of which are outlined in the Company’s most recent 10-K and subsequent 10-Qs, which may cause the actual performance of Flotek to be materially different from any future results expressed or implied in this presentation and the forward-looking statements. Flotek undertakes no obligation to update any of its forward-looking statements for any reason.
Contained in this slide deck are transactional and financial reporting information.
In some cases, estimates or approximations may be used. While footnotes are intended to explain such cases, they may not be all inclusive in the procedures taken to report transactional or customer specific information.
This presentation may contain measures that are not calculated based on accounting principles generally accepted in the United States of America, also known as GAAP. Information regarding those non-GAAP financial measures and the reconciliations of the non-GAAP financial measures to the most directly comparable GAAP measures are provided in the Appendix of this presentation and in the Company’s earnings press releases, which can be found on the Company’s web site www.Flotekind.com.
2
18%
82%
InternationalDomestic
• NYSE: FTK
• Market Cap: $114.8MM(1)
• Cash: $97.5MM & No Debt(2)
• TTM Revenue: $175.1MM (3)
• Portfolio of 138 patent assets and growing(4)
Company Overview
Evolving Business Model
2015
<15%2018
>75%
Applying Innovative Chemistry
(1) Based on 57,697,905 shares outstanding as of 7/31/2019, and market closing price of $1.99 on 8/9/2019.(2) As of 6/30/2019.(3) Based on Trailing Twelve Months (“TTM”) ended 6/30/2019.(4) As of 8/5/2019, includes patents granted and pending applications.
2018 Revenue Mix Anchored by North America
% Domestic Sales Direct to E&P
• Reflective of broader industry trends
• E&P customers seeking decoupled prices
• Closer alignment with individual reservoirs
Custom Chemistry
Summary Metrics
3
Strategically Positioned
Latin
Am
eric
aEu
rope
/ M
E / R
ussia
Asia
Pac
ific
Flotek Sales / Operations Current Flotek TargetsCountries with Significant Unconventional Resources
Inte
rnat
iona
l Rea
ch4
500+Prescriptions Across U.S. in 2017 & 2018
Flotek Recommends Custom Chemistry Across North America and Basins Around the World
Key Investment Thesis
Driving Higher Oil and Gas Reservoir Recovery and Meaningful Returns Through Innovative Applications of Chemistry
~$109MM net cash proceeds from sale of Florida Chemical Company(1)
In 2019, announced & executed on cost reductions of >$25MM on annualized basis, and additional cost saving opportunities identified
Strategic Capital Committee formed and currently reviewing use of proceeds
Proven field results on thousands of wells from reservoir -centric full fluid designs
Proprietary solutions driving lower cost-per-barrel incremental production
E&Ps turning to performance-enhancing chemistries to drive greater value as mechanical completion designs reaching limits of effectiveness
Operators directly sourcing consumables – including chemistry – to drive structural cost optimization across upstream supply chain
1
2
3
(1) Net proceeds from Florida Chemical Company (“FCC”) sale post debt paydown; includes $15.7mm in funds reflecting Flotek’s estimated claim to funds temporarily held in escrow. Sale closed 2/28/2019.
Disciplined Approach to Growth and Profitability
Leading Developer of Performance Chemistry
Attractive Market Dynamics
Flotek is Ideally Positioned to Execute on Unique Opportunity
5
Proprietary Chemistry Solutions
Prescribed for the Reservoir
Integrated Technical
Expertise for Unique Knowledge
of Chemistry Applications
Extensive Database Of Fluid System Performance
UNIQUELY ADDING
VALUE TO E&Ps
Why Flotek?
Why Now?
7
• E&Ps and oilfield service (OFS) providers under heightened pressure by capital markets to drive increased capital efficiency and preserve liquidity
• E&Ps focused on driving greater asset productivity through combination of lower cost per barrel, increased production and maximum economic ultimate recovery (EUR) from reservoir
• Opportunity for further cost reductions from OFS providers and supply chain partners is limited
• Increasing recognition of diminishing returns as mechanical variables (lateral length, level of proppant loading, number of fracs, frac stages per foot, etc.) reach or exceed economic and technical limits in certain basins
• E&Ps beginning to focus on other technologies – including chemistry – to meaningfully and reliably enable productivity
Upstream Oil & Gas
Oilfield Services(1)
• OFS segment has never been more fragmented than it is today
• >1,000 listed and private companies globally with only six companies having market cap >US$10 billion
• Market share of top 25 companies in OFS segment’s revenue currently at low level of 52% (400 basis point decrease from 2014)
• To ensure long-term success, OFS companies must provide differentiated technology and develop new/innovative commercial models throughout value chain
Flotek at Forefront of Providing Industry-Leading Reservoir-Centric Chemistry Solutions that Drive Greater Capital Effectiveness and ROI
E&Ps Recognizing Custom Chemistry as Means to Achieving Optimal Economic Recovery of Hydrocarbons from Reservoir as Other Means Reach Limits
(1) “Decoding the Oil & Gas Downturn”, Deloitte, April 2019.
Controlling the “Controllables”
8
• Evolve business model and improve internal processes while prudently taking costs out of business to drive increased efficiency and profitability
• Closely collaborate with operators to identify and define industry challenges
• Enhance sales team and related process to further build technical peer-to-peer relationships with specific individuals that have ultimate decision-making responsibility for chemistry purchases
• Clearly communicate significant benefits Flotek’s technologies can have on client's bottom line results
• Utilize innovative commercial strategies to accelerate further adoption of product offerings
• Evaluate opportunities that will provide greater scale and immediate positive operating cash flow, while building on and enhancing core competencies
(1) “Decoding the Oil & Gas Downturn”, Deloitte, April 2019.
Flotek Will Continue to Provide Clients With Best-in-Class Chemistry Solutions and Drive Additional Operational
Effciencies, While Evaluating Opportunities to Prudently Grow Business and Immediate Cash Flow
Right Sizing Business to Promote Future Success
(1) SBC = stock-based compensation(2) Excludes depreciation and amortization and gains/losses on disposal of long-lived assets9
Relative Share of 2019 Consolidated Operating Costs Reduction Targets(2)
Corporate G&A and R&I, excluding SBC(1)
(Quarterly; $mm)
~$21MM of annualized cost reductions since Q2 2017 >$25MM of annualized cost reductions for 2019
Since 2017, Transitioned from Four Business Units to One and Aggressively Reduced Cost Structure
201820172016
2015
2014
2013
2012
201820172016
2015
2014
20132012
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
3,00
0
4,00
0
5,00
0
6,00
0
7,00
0
8,00
0
9,00
0
10,0
00
201820172016
2012
2012
2016 20172018
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
500
700
900
1,10
0
1,30
0
1,50
0
1,70
0
1,90
0
2,10
0
2,30
0
2,50
0
New Technologies Needed to Improve Returns
Source: RS Energy
3 M
onth
BO
E C
umul
ativ
e V
olum
es p
er 1
000’
Delaware Midland(lbs/ft) (ft)
Diminishing returns from mechanical completion optimization illustrates need for custom chemistry as “next leg” of improving returns
Indicates Period of Diminishing Returns
Proppant Intensity Lateral Length
3 M
onth
BO
E C
umul
ativ
e V
olum
es p
er 1
000’
Indicates Period of Diminishing Returns
10
Prescriptive Chemistry Driving Capital Effectiveness
Lower chemistry costs with direct sourcing
Tailor & design fluid systems to lower overall costs
Opportunity to optimize performance with less proppant loading
Enable more effective use of produced waters
Minimize horsepower requirements through prescribed fluid systems
Demonstrated history of:
Increased well performance
Higher initial production as seen in production decline curves
Payback between 1 – 3 months
Improving economics by lowering the gas-to-oil ratio
FROM CAPITAL EFFICIENCY TO CAPITAL EFFECTIVENESS
11
Designed & tailored fluid system for reservoir
Moved from $8/gal to more effective $11/gal chemistry, at lower dosages
Significantly reduced operational costs from horsepower (HHP) by $1.5M
Reduced fluid-reservoir incompatibility, further reducing operational costs - $250,000/well within the first year
Well ProgramPer Month
Total Cost Benefit
Flotek partnered with a MidCon operator to design and tailor their fluid system for their reservoir. By switching to a more effective fluid system, we were able to:
• reduce overall chemistry spend per well,
• optimize horsepower efficiency, and
• reduce fluid-reservoir incompatibility
$380,000Per Well
$1.9mmPer MonthFor 5-Well Program
$20mm+Per Year(1)
Reduced chemistry spend -$150k for 5 wells/month
Case Study on How Prescriptive Chemistry Management® (PCM®) Creates Value for Our Clients
Value Proposition: Customized Fluid Design and Cost Benefits
(1) Assuming an illustrative 5-well program per month for one year.
Flotek Customized Design Less Equipment Needed Reduce Cost of Ownership
5
12
Industry Mitigation Strategies(1)
MITIGATION STRATEGY FLUID CHEMISTRY
Increase lateral spacing
Reduce infill treatment size
Shut-in primary well
Fluid pre-load of primary well
Preventative refrac on primary well
Zipper frac, simul-frac, modified zipper frac
Cube development
(1) SOURCE: SPE 191712-MS | BHP(2) As reported by JPT “To Solve Frac Hits, Unconventional Engineering Must Revolve Around Them,” 2/8/2019
Reservoir-Centric Chemistry to Prevent & Remediate Frac Hits
+ Mitigate damage due to frac interactions
+ Remediate near wellbore damage due to frac interactions
FRAC-DRIVEN INTERACTIONS DEPEND ON PRIMARY WELL DEPLETION RELATIVE TO INFILL WELL FORMATION PRESSURE AND SPACING
CUSTOMIZED FLUID CHEMISTRY CAN BE USED IN PRIMARY WELLS TO:
FLUID CHEMISTRY TAILORED FOR RESERVOIR CHARACTERISTICS SHOULD BE USED ON INFILL WELL STIMULATIONS
70% of New Wells Drilled in U.S. Onshore Will Be Infill Wells(2)
13
Woodford Well A Daily Production Expressed as Percent Of Well A’s 30-day Pre Frac-Hit Rates
Figure 24 – Woodford Well A production rates returned to pre frac-hit decline trend after remediation
SOURCE: URTeC 2902400 | Apache, Flotek
Reservoir-centric chemistry prescription recovers production
Treatment
Case Study: Mitigation of Negative Frac-Driven Interactions Woodford
14
Flotek Experience in the Midland and Delaware Basin
Flotek Prescription Areas
In 2017 & 2018 , Flotek completed more than
Prescriptions in the Midland and Delaware Basins
19015
Source: RS Energy
The CnF® population outperforms the population without CnF®.
Payout periods are longer for the well population without CnF®.
CnF® Performance – Wolfcamp AMidland, Martin & Upton County
16
The CnF® population outperforms the population without CnF®.
Data source: RS Energy
CnF® Performance – Wolfcamp BMidland, Martin & Upton County
Source: RS Energy Group17
ORGANIC
Prudently Growing the Business
INORGANIC
EXPANDS OFFERINGS ACROSS THE FULL LIFE CYCLE OF THE WELL
CAPITAL LIGHT
BUILDING & ENHANCING CORE COMPETENCIES
IMPROVED PROFITABILITY
CONTRIBUTES IMMEDIATE & STABLE POSITIVE CASH FLOW
PRODUCT INNOVATION GROWTH WITH CLIENTS OF SCALE STRATEGIC PARTNERSHIPS EXPANSION OF ENHANCED OIL RECOVERY
GREATER SCALE
18
Strategic Capital Committee Evaluating Alternatives For Best Use of Net Proceeds from Sale of Florida Chemical
SIGNIFICANT
Uniquely Positioned for Long-Term Success
19
Leading Developer of Performance Chemistry
Attractive Market Dynamics
Disciplined Approach to Growth and Profitability
APPENDIX
20
Business Update
21
• Ended quarter with no debt and cash of $97.5MM, which was level with Q1 2019
• Generated revenue of $34.7MM and Adjusted EBITDA loss of $9.6MM
• Operated in continued volatile macro-environment for U.S. onshore drilling and completion and directly impacted by:
• Substantial turnover of sales team and commencement of rebuilding and development of more technically oriented sales organization
• Deferral of completion activity to Q3 2019 by certain clients
• Utilization of performance-driven pricing programs for limited number of strategic clients
Q2 2019
Cost Optimization
Strategic Capital Committee
• In mid-July, implemented >$5MM of annualized cost-cutting initiatives, primarily associated with ECT personnel and other operating expenses
• To date for 2019, announced and executed on initiatives that reduce annual cash costs >$25MM across enterprise
• Currently evaluating additional opportunities to drive greater profitability through order-to-cash efficiencies, including process enhancements to sales, supply chain and logistics
• From Q2 2017 to Q2 2019, removed ~$21MM, or 44%, in annualized spending related to corporate general and administrative and research and innovation support functions, excluding stock-based compensation expense
• Continuing to evaluate alternatives for use of net proceeds from the sale of Florida Chemical Company
• Recently completed deep-dive review of ongoing business
• Near-term focus on possibility of investments in organic and inorganic opportunities, providing greater scale and immediate positive operating cash flow, while building on and enhancing core competencies
Domestic Market Sizing
Source: Wall Street Research, Spears & Associates, FTK estimates.Note: Based on 2018 estimates.
Total Lower 48 D&C Spending
Completion Chemistry Average Spend per Horizontal Well
Global Specialty Chemicals Market
$100bn
~15k 3 – 6%
$6.6bn
Horizontal Well Completions
$4Billion
Flotek Domestic Addressable Market
22
Recent Financials
23
6/30/2019 6/30/2018 3/31/2019 6/30/2019 6/30/2018
Revenue $ 34,692 $ 39,546 $ 43,256 $ 77,949 $ 80,615 Costs and expenses:
Operating expenses (excluding depreciation and amortization) 38,306 35,544 44,599 82,904 72,199 Corporate general and administrative 6,054 8,665 7,281 13,335 17,158 Depreciation and amortization 2,119 2,343 2,260 4,379 4,676 Research and development 2,076 2,949 2,285 4,360 5,704 (Gain)/loss on disposal of long-lived assets (4) 5 1,097 1,093 62 Impairment of goodwill - 37,180 - - 37,180
Total costs and expenses 48,551 86,686 57,522 106,071 136,979 Loss from operations (13,859) (47,140) (14,266) (28,122) (56,364)Other (expense) income:
Interest expense (16) (640) (1,998) (2,014) (1,156)Loss on write-down of assets held for sale - (2,580) - - (2,580)Other income (expense), net 693 (2,499) 110 800 (2,609)
Total other expense 677 (5,719) (1,888) (1,214) (6,345)Loss before income taxes (13,182) (52,859) (16,154) (29,336) (62,709)Income tax benefit (expense) 192 (16,128) 774 966 (15,807)Loss from continuing operations (12,990) (68,987) (15,380) (28,370) (78,516)Income (loss) from discontinued operations, net of tax (1,608) (6,404) 48,372 46,764 3,192
Net income (loss) (14,598) (75,391) 32,992 18,394 (75,324)Net income attributable to noncontrolling interests - 357 - - 357
Net income (loss) attributable to Flotek Industries, Inc. (Flotek) $ (14,598) $ (75,034) $ 32,992 $ 18,394 $ (74,967)Amounts attributable to Flotek shareholders:
Loss from continuing operations $ (12,990) $ (68,630) $ (15,380) $ (28,370) $ (78,159)Income (loss) from discontinued operations, net of tax (1,608) (6,404) 48,372 46,764 3,192
Net income (loss) attributable to Flotek $ (14,598) $ (75,034) $ 32,992 $ 18,394 $ (74,967)Basic & diluted earnings (loss) per common share:
Continuing operations $ (0.22) $ (1.19) $ (0.26) $ (0.49) $ (1.36)Discontinued operations, net of tax (0.03) (0.11) 0.83 0.80 0.06
Basic & diluted earnings (loss) per common share $ (0.25) $ (1.30) $ 0.57 $ 0.31 $ (1.30)
Six Months EndedThree Months EndedUnaudited Condensed Consolidated Statements of Operations($000’s)
Unaudited & in $000’s
Reconciliation to Adjusted EBITDA (Non-GAAP)
24
Three Months Ended Six Months Ended6/30/2019 6/30/2018 3/31/2019 6/30/2019 6/30/2018
Loss from Continuing Operations (GAAP) (12,990)$ (68,987)$ (15,380)$ (28,370)$ (78,516)$
Interest Expense 16 640 1,998 2,014 1,156
Interest Income (685) (52) (226) (912) (235)
Income Tax Benefit Expense (192) 16,128 (774) (966) 15,807
Depreciation and Amortization 2,119 2,343 2,260 4,379 4,676
EBITDA (Non-GAAP) (11,732)$ (49,928)$ (12,122)$ (23,855)$ (57,112)$
Stock Compensation Expense 1,213 2,357 456 1,669 4,257
Severance and Retirement 356 105 1,721 2,077 122
Shareholder-Related Activities 71 - 581 652 -
Operations Related Contract Termination 500 - - - -
Inventory Write-down - - - - 1,000
Impairment of Goodwill - 37,180 - - 37,180
Loss on Write-down of Assets Held for Sale - 2,580 - - 2,580
Loss (Gain) on Disposal of Assets (4) 5 1,097 1,093 62
Discontinuation of Corporate Projects - 1,220 - - 1,220
Expenses Relating to Closing of Business Venture - 436 - - 436
Adjusted EBITDA (Non-GAAP) (9,596)$ (6,045)$ (8,267)$ (18,364)$ (10,255)$
* Management believes that adjusted EBITDA for the three and six months ended June 30, 2019 and June 30, 2018, and the three months ended March 31, 2019, is useful to investors to assess and understand operating performance, especially when comparing those results with previous and subsequent periods. Management views the expenses noted above to be outside of the Company's normal operating results. Management analyzes operating results without the impact of the above items as an indicator of performance, to identify underlying trends in the business and cash flow from continuing operations, and to establish operational goals.
Unaudited & in $000’s
Reconciliation to Adjusted Net Income (Non-GAAP)
25
Three Months Ended Six Months Ended6/30/2019 6/30/2018 3/31/2019 6/30/2019 6/30/2018
Loss from Continuing Operations (GAAP) (12,990)$ (68,987)$ (15,380)$ (28,370)$ (78,516)$
Deferred Tax Asset Valuation Allowance - - - - -
Select Items Impacting Earnings, net of tax 729 32,806 3,760 4,094 33,654
Adjusted Net Loss (Non-GAAP) (12,261)$ (36,181)$ (11,620)$ (24,276)$ (44,862)$
Weighted Average Shares Outstanding (Fully Diluted) 58,608 57,869 58,373 58,491 57,566
Adjusted Loss Per Share (Fully Diluted) (0.21)$ (0.63)$ (0.20)$ (0.42)$ (0.78)$
Select Items Impacting Earnings
Severance and Retirement 356 105 1,721 2,077 122
Shareholder-Related Activities 71 - 581 652 -
Operations Related Contract Termination 500 - - - -
Inventory Write-down - - - - 1,000
Impairment of Goodwill - 37,180 - - 37,180
Deferred Financing Costs - - 1,360 1,360 -
Loss on Write-down of Assets Held for Sale - 2,580 - - 2,580
Loss (Gain) on Disposal of Assets (4) 5 1,097 1,093 62
Discontinuation of Corporate Projects - 1,220 - - 1,220
Expenses Relating to Closing of Business Venture - 436 - - 436
Total Select Items 923$ 41,526$ 4,759$ 5,182$ 42,600$
Less income tax effect (21%) (194) (8,720) (999) (1,088) (8,946)
Select Items Impacting Earnings, net of tax 729$ 32,806$ 3,760$ 4,094$ 33,654$
* Management believes that adjusted Net Income for the three and six months ended June 30, 2019 and June 30, 2018, and the three months ended March 31, 2019, is useful to investors to assess and understand operating performance, especially when comparing those results with previous and subsequent periods. Management views the expenses noted above to be outside of the Company's normal operating results. Management analyzes operating results without the impact of the above items as an indicator of performance, to identify underlying trends in the business and cash flow from continuing operations, and to establish operational goals.
Investor Relations Contact
CORPORATE HEADQUARTERS:
10603 W. Sam Houston Pkwy. N.
Suite 300
Houston, TX 77064
INVESTOR RELATIONS:
Email: [email protected]
Phone: (713) 726-5367
26